(MT Newswires) -- Pfizer Inc. (PFE) is purchasing cancer-drug maker Seagen Inc. (SGEN) for an enterprise value of $43 billion, using the biggest deal of the year to set its course out of the pandemic and back into mainstream pharma. Pfizer CEO Dr. Albert Bourla speaks to David Westin.
INTERVIEW - Pfizer CEO Albert Bourla on the Seagen deal, growth and regulatory risks
![INTERVIEW - Pfizer CEO Albert Bourla on the Seagen deal, growth and regulatory risks](https://cdn.zonebourse.com/static/resize/464/261/https://www.zonebourse.com/images/ImagesTagged/zbimg_12014_800.png)
![mtnewswires logo](/images/mtnewswires.png)